ASCO GUIDELINES Bundle

Dyspnea in Advanced Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475459

Contents of this Issue

Navigation

Page 3 of 13

4 Treatment 4. Non-pharmacologic Interventions ➤ Airflow interventions such as directing a fan at the cheek (trigeminal nerve distribution) should be offered. (Moderate recommendation; EB-I) ➤ Standard supplemental oxygen should be available for patients with hypoxemia who are experiencing dyspnea (i.e., SpO 2 ≤90% on room air). (Moderate recommendation; EB-I) ➤ Supplemental oxygen is not recommended when SpO 2 >90%. (Moderate recommendation; EB-I) ➤ A time-limited therapeutic trial of high flow nasal cannula oxygen therapy, if available, may be offered to patients who have significant dyspnea and hypoxemia despite standard supplemental oxygen. (Moderate recommendation; EB-L) ➤ A time-limited therapeutic trial of non-invasive ventilation, if available, may be offered to patients who have significant dyspnea despite standard measures and do not have contraindications. (Moderate recommendation; EB-L) ➤ Other non-pharmacologic measures such as breathing techniques, posture, relaxation, distraction, meditation and education/self- management, physical therapy, and music therapy may be offered. (Weak recommendation; EB-L) ➤ Acupressure/reflexology, if available, may be offered. (Weak recommendation; EB-L) ➤ Evidence remains insufficient for a recommendation for or against pulmonary rehabilitation in patients with advanced cancer and dyspnea.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Dyspnea in Advanced Cancer